ABSTRACT
Objective:To evaluate the short-term efficacy and safety of Apollo stent in the treatment of symptomatic basilar artery stenosis.Methods:Patients with symptomatic basilar artery stenosis admitted to the Fourth Affiliated Hospital of China Medical University from January 2017 to May 2020 were selected and treated with Apollo stent implantation. The changes of clinical symptoms and the success rate of operation were evaluated. Postoperative complications included symptomatic intracranial hemorrhage, hyperperfusion, and new ischemic stroke, and follow-up results were evaluated 3 to 6 months later.Results:A total of 96 patients were included in this study, and all of them were confirmed by angiography to have severe basilar artery stenosis corresponding to the symptoms. Among them, 88 patients received stent implantation, with a success rate of 100%. Among the 88 patients, 86 received Apollo stent implantation, and 2 patients received self-Peng stent implantation. Among 86 patients with Apollo stent implantation, the lesions were located in the proximal segment in 73 cases (84.88%), in the middle segment in 10 cases (11.63%), and in the distal segment in 3 cases (3.49%). The degree of stenosis was (93.72±3.86)%, the length of stenosis was (8.50±2.65)mm, the residual stenosis rate was (1.76±4.87)%, and Mori type A lesions in 80 cases, type B lesions in 3 cases, and type C lesions in 3 cases. Among 86 patients with Apollo stent implantation, the incidence of perioperative neurological complications was 6.98%(6/86), including 1 case in the proximal part of the basilar artery (vascular rupture), 3 cases in the middle part of the basilar artery (perforating artery occlusion in 1 case, acute thrombosis artery occlusion in 2 cases), and 2 cases in the distal part (both acute vascular occlusion). Alteplase was injected into the microcatheter during the operation, and contact thrombolysis was performed. Immediately digital subtraction angiography (DSA) showed that the blood vessels were opened, and 1 case with neurological deficit was left. No hyperperfusion occurred in all patients. All patients were followed up for three months after operation. Among them, 58 patients had a good prognosis in the proximal segment of the basilar artery, 18 patients had a good prognosis in the middle segment, 4 patients had a good prognosis in the distal segment, and 6 patients had a bad prognosis (1 patient died). Postoperative stent restenosis occurred in 5 cases (5.81%), recurrent stroke in 3 cases (3.49%), and disabling stroke in 1 case (1.16%).Conclusions:Apollo stent is safe and effective in the treatment of symptomatic basilar artery stenosis, with good short-term prognosis, and long-term prognosis needs to be further studied.
ABSTRACT
<p><b>OBJECTIVE</b>To study the therapeutic effect of intranasal administration of temozolomide (TMZ) for brain-targeting delivery in a rat model bearing orthotopic C6 glioma xenografts.</p><p><b>METHODS</b>Forty Wistar rat bearing brain C6 glioma xenograft were randomly divided into 4 groups and treated with physiological saline solution or with TMZ by intravenous injection, gavage or intranasal administration. The tumor size, rat survival time and pathological changes were observed in each group.</p><p><b>RESULTS</b>Magnetic resonance imaging showed a significantly reduced volume of glioma in intranasal TMZ group compared with that in the control, intraveneous TMZ injection group and TMZ gavage groups (12.45∓2.49 mm(3) vs 60.16∓4.12, 33.17∓3.56, and 35.16∓4.36 mm(3), respectively, P<0.05). The median survival time of the C6 glioma-bearing rats was also significantly longer in intranasal TMZ group than in the other 3 groups (31.0 days vs 20, 19, and 21.5 days, respectively, P<0.05). In the glioma xenografts, PCNA expression was the lowest and tumor cell apoptosis rate the highest in intranasal TMZ group.</p><p><b>CONCLUSION</b>Intranasal TMZ administration can suppress the growth of C6 glioma in rats and may serve as an effective strategy for glioma treatment.</p>
Subject(s)
Animals , Rats , Administration, Intranasal , Antineoplastic Agents, Alkylating , Apoptosis , Brain Neoplasms , Drug Therapy , Cell Line, Tumor , Dacarbazine , Drug Delivery Systems , Glioma , Drug Therapy , Magnetic Resonance Imaging , Neoplasm Transplantation , Rats, WistarABSTRACT
Despite multimodel chemotherapy after successful surgical cytoreduction for ovarian cancer,disease recurrence continues to be problematic.Therefore,exploring new treatment strategy has already become urgent matter of the moment. Biological targeted therapies have been studied to overcome chemotherapy resistance.The most promising one at this time is bevacizumab.Results from phase Ⅱ and phase Ⅲ trials were excited.Deeper understanding of biologic pathway in ovarian cancer,and more biologic targets undergoing clinical trial will develop a new world for the treatment of ovarian cancer.
ABSTRACT
Objective To investigate the pathogenesis,high risk factors,clinical characteristics,methods of diagnosis and treatment,and prognosis of vaginal intraepithelial neoplasia (VAIN).Methods The clinical data of thirteen cases of VAIN treated in Zhejiang Provincial Cancer Hospital dated Mar.2002 through Dec.2008 were reviewed and analyzed retrospectively.Results Twelve of 13 VAIN cases were performed the human papillomavirus(HPV) detection with 92% (11/12) HPV positive rate.None of the cases shown specific clinical manifestation.Among the 13 cases,6 of them accompanied with cervical cancer,4 cases with cervical intraepithelial neoplasia (CIN ),and 3 cases with vulvar intraepithelial neoplasma (VIN).Five cases synchronously diagnosed with cervical lesion and 3 with vulva lesion were underwent surgery,while the other 5 cases were diagnosed metachronously.Among 8 cases underwent surgery,1 case with CIN underwent argon plasma coagulation (APC) after surgery,1 case with the positive edge of VIN underwent APC.During follow up,1 case with locally advanced cervical cancer underwent radiotherapy again,3 cases with VAIN received APC,while 1 cervical cancer cases with VAIN received no treatment.The average follow-up time was 25.6 months (range 6-87 months).Two cases died of cervical cancer metastasis.The other 11 cases were normal and still alive.None of them progressed to invasive carcinoma.Conclusions The main reason of VAIN is HPV infection.There are not specific clinical manifestations,usually diagnosed when reviewing cervical or vulva lesions and rarely progressed to invasive carcinoma.The main treatment of VAIN is surgery with the adjuvant treatment of APC.
ABSTRACT
Objective To study the clinical feature and treatment of lung benign metastasizing leiomyoma. Methods A retrospective analysis was performed on 2 cases of lung benign metastasizing leiomyoma. Results Two cases were asymptomatic who also had previously undergone hysterectomy, but imageology revealed multiple pulmonary nodules bilaterally of various sizes. And one of them had a pelvic mass. Conclusion Lung benign metastasizing leiomyoma is a rare disease. Hysterectomy, bilateral salpingo-oophorectomy and hormonal therapy may be helpful to improve the prognosis.
ABSTRACT
In recent years, many surgical innovations have been made from cervical cancer, such as trachelectomy, laparoscopic radical hysterectomy and surgery for advanced or recurrent cervical cancer, etc. The surgical innovations improve treatment effects, as well as postoperative quality of life.
ABSTRACT
The pharmacodynamics of prostaglandin E1 (PGE1) administered by different routes to rats was investigated in this paper. The hypotensive effect of PGE1 was used as an index of drug efficacy, pharmacodynamic parameters such as time to reach peak effect (Tmax), maximal percentage of blood pressure decrease (Emax, %), duration of effect (Td), and the area determined after PGE1 given to rats intranasally, sublingually, intraperitoneally (ip),and intramuscularly (im), separately, and compared with those obtained from intravenous (iv) administration. Similar to iv route, the pharmacodynamic parameters of PGE1 from the other administration routes, Emax, Td and in particular AUC values were all increased with increasing doses, showing dose-efficacy relationship. Tmax was found to be approximately 3-4 min for nasal route, 3-8 min for im, 6-8 min for ip and 12-30 min for sublingual route, separately. Thus, the order of magnitude of absorption rate of the drug was as follows: nasal≈im＞ip＞sublingual. If the pharmacological bioavailability (PF) for each administration route was used as a tentative measure of drug absorption extent, the order of magnitude of absolute bioavailability appeared as follows: nasal＞im≈ip＞sublingual. Furthermore, the interindividual difference was found to be larger for im and ip route than that for nasal and sublingual route. These results indicate nasal and sublingual routes are two promising routes for the systemic delivery of PGE1 in clinical applications.
ABSTRACT
OBJECTIVE:To establish a HPLC method for determination of the principal components and the related substances in compound ftibamzone/dyclonine liniment. METHODS: The determination was performed on MACHEREY-NAGEL C18 chromatographic column with the mobile phase consisted of methanol-acetonitrile-0.02 mol?L-1 potassium dihydrogen phosphate solution-triethylamine (25∶25∶50∶0.3,pH value adjusted to 4.0 by the phosphoric acid) with a flow rate of 1.0 mL?min-1. The UV detection wavelength was set at 295 nm. RESULTS: A baseline separation was achieved between foreign materials’ peaks and the principal agents’ peaks. The calibration curve of ftibamzone and dyclonine were linear within the ranges of 20.63～72.21 ?g?mL-1(r=0.999 9) and 20.44～71.54 ?g?mL-1 (r=0.999 9),respectively;the average recovery rate was 98.7% vs. 99.2%;the inter-day RSD was 0.97% vs. 1.10%;the intra-day RSD was 1.52% vs. 1.75%,and the lowest detective limit was 0.4 ng vs. 0.2 ng. The contents of the related substances were ranged from 0.43% to 0.68%. CONCLUSION: This method is simple,rapid,specific,accurate and reproducible,and it can be used for the quality control of the compound ftibamzone/dyclonine liniment.
ABSTRACT
The treatment for endometrial cancer refers to surgery,radiation and chemotherapy.Some disputable issues in the treatment are existing.Based on the recent clinical trial results,the choice of surgical modality,the role of lymphadenectomy,radiation and chemotherapy are present and discussed in this article.
ABSTRACT
<p><b>OBJECTIVES</b>To study the difference between gene expressions of high (H0-8910PM) and low (HO-8910) metastatic human ovarian carcinoma cell lines and screen novel associated genes by cDNA microarray.</p><p><b>METHODS</b>cDNA retro-transcribed from equal quantities of mRNA derived from high and low metastatic tumor cells or normal ovarian tissues were labeled with Cy5 and Cy3 fluorescein as probes. The mixed probe was hybridized with two pieces of BioDoor 4096 double dot human whole gene chip and scanned with a ScanArray 3000 laser scanner. The acquired image was analyzed by ImaGene 3.0 software.</p><p><b>RESULTS</b>A total of 355 genes with expression levels more than 3 times larger were found by comparing the HO-8910 cell with normal ovarian epithelial cells. A total of 323 genes with expression levels more than 3 times larger in HO-8910PM cells compared to normal ovarian epithelium cells were also detected. A total of 165 genes whose expression levels were more than two times those of HO-8910PM cells compared to their mother cell line (HO-8910) were detected. Twenty-one genes with expression levels > 3 times were found from comparison of these two tumor cell lines.</p><p><b>CONCLUSIONS</b>cDNA microarray techniques are effective in screening differential gene expression between two human ovarian cancer cell lines (H0-8910PM; HO-8910) and normal ovarian epithelial cells. These genes may be related to the genesis and development of ovarian carcinoma. Analysis of the human ovarian cancer gene expression profile with cDNA microarray may help in gene diagnosis, treatment and prevention.</p>
Subject(s)
Female , Humans , Gene Expression Profiling , Neoplasm Metastasis , Oligonucleotide Array Sequence Analysis , Ovarian Neoplasms , Genetics , Pathology , Tumor Cells, CulturedABSTRACT
Purpose:To evaluate the efficacy and toxicities of gemcitabine plus cisplatin for patients with relapsed ovarian cancer. Methods:Twenty-eight patients with recurrent ovarian carcinoma received gemcitabine (1000 mg/m~(2)) plus cisplatin (35 mg/m~(2)) on days 1 and 8 of each 21-day cycle. Of 28 patients, sixteen who relapsed within six months of previously platinum-based regimen were platinum-resistant and the other twelve were platinum-sensitive. Results:Of 28 patients, there were 5 (17.9%) complete and 12 (42.9%) partial responses, for an overall response rate of 60.7% (95%CI: 41.7%–79.6%). The median time to progression for objective responders was 5.5 months with a range of 2.5 to 20 months. Median overall survival for all 28 patients was 12.5 months. Among 16 platinum-resistant patients, a 56.3% response rate occurred. The median survival time was 10.5 months. Among 12 platinum-sensitive patients, a 66.7% response rate occurred. The median survival time was 14.5 months. There were leukopenia grade Ⅲ in 35.7%, grade Ⅳ in 17.9%; thrombocytopenia grade Ⅲ in 28.6 %, grade Ⅳ in 14.3% of patients. Conclusions:Cisplatin plus gemcitabine is active in patients with relapsed ovarian cancer. The adverse effects are tolerable. Hematologic toxicities are manageable with dose modifications.
ABSTRACT
Purpose:To study the role of postoperative radiotherapy in early stage uterine sarcomas. Methods:Retrospective analysis of the impact of radiotherapy on progress-free survival rate (PRS )rate, local recurrence rate (LRR) and overall survival (OS)in stage Ⅰ,Ⅱ uterine sarcomas. 34 cases were treated with surgery alone ,42 cases were treated with postoperative radiotherapy. Results:The PRS at 2 and 5 years for surgery were 38.2% and 26.5% ,69.0% and 57.1%for postopeative radiotherapy. The LRR at 2 and 5 years treated with surgery were 52.9% and 64.7%,26.2% and 28.6% with adjuvant irradiation. The OS at 2 and 5 years treated with surgery were 83.4%and 47.0%,83.3% and 69.0% with adjuvant radiation. Conclusions:Postoperative radiotherapy showed a marked increase in the three parameters studied (PRS? LRR?OS ) for I,II stage uterine sarcomas.
ABSTRACT
Purpose:To study the adjuvant therapy in uterine sarcomas,to decrease local recurrence and metastases and improve survival.Methods:Analysis of the management of 113 cases of uterine sarccoma , retrospectively. 30 cases were treated weith surgery alone , 25 with adjuvance radiation , 34 with postoperative chemotherapy, 21 with surgery and chemo radiation.Results:The 2 year pelvic recurrence and metastases with surgery alone were 43.3 % and 30 0 %,32 0 % and 28 0 % with postoperative radiation,44.1 % and 20.6 % with postoperative chemotherapy, 23.8 % and 23.8 % with postoperative combination of chemo radiation.But there was no significant difference between surgery alone and postoperative adjuvant therapy.Conclusions:Postoperative radiotherapy can improve local control,adjuvant chemotherapy can decrease metastases,both can improve disease free survival,but can not improve overall survival for uterine sarcomas.
ABSTRACT
This paper reports the treatment of 65 cases with Verruca Acuminate, 35 cases with the fulguration while 30 cases with the combined fulguration with injection poly i:c and both were compared. The results showed that the cure rate of the fulguration group was 68.6%, and that of the combined therapy group was 96,5%. The cure rate of the latter group revealed higher (P